BioCentury | Jul 24, 2014
Cover Story

It is an RNA world

...antisense oligonucleotide Phase III Topical eye drops Gene Signal International S.A....
...an antisense oligonucleotide Ophthalmic disease Corneal neovascularization Gene Signal International S.A....
...IRS1) mRNA, in Phase III testing by Gene Signal International S.A....
BioCentury | May 19, 2014
Clinical News

Aganirsen: Phase III data

...risk of graft rejection, QOL and complete ophthalmic evaluation scores at day 90 vs. placebo. Gene Signal...
...standard of care (SOC) including corticoids, antiviral and immunosuppressant therapies. Data were published in Ophthalmology. Gene Signal...
...occlusion (CRVO) and Phase II testing to treat wet age-related macular degeneration (AMD). In 2015, Gene Signal...
BioCentury | May 13, 2014
Clinical News

Gene Signal publishes mixed data for aganirsen

...Data published in Ophthalmology showed that twice-daily aganirsen ( GS-101 ) eye drops from Gene Signal International S.A. (Lausanne...
...bacterial, viral or traumatic origin in the intent-to-treat (ITT) population of the double-blind, European trial. Gene Signal...
BioCentury | Apr 28, 2014
Clinical News

Aganirsen: Phase IIa data

...burning or exudation reported. Data were published in The Journal of Pharmacology and Experimental Therapeutics. Gene Signal...
...Aganirsen has also completed a European Phase III trial to treat neovascular-associated corneal graft rejection. Gene Signal International S.A....
BioCentury | May 16, 2013
Distillery Therapeutics

Indication: Cancer

...developing an assay to screen for small molecules that could disrupt the IRS1-mutant p110a interaction. Gene Signal International S.A.'s...
BioCentury | Apr 1, 2013
Strategy

Shire sees opportunity

...for life-altering diseases," Ornskov said. Premiplex is the most advanced ROP program in the clinic. Gene Signal International S.A....
...NYSE:AGN), Irvine, Calif. Bausch & Lomb Inc. , Rochester, N.Y. Bayer AG (Xetra:BAYN), Leverkusen, Germany Gene Signal...
BioCentury | Jan 28, 2013
Financial News

Gene Signal completes venture financing

Gene Signal International S.A. , Lausanne, Switzerland Business: Ophthalmic Date completed: 1/23/13 Type: Venture financing Raised: Not disclosed Investors: Individual investors WIR Staff Ophthalmic...
BioCentury | Sep 21, 2009
Product Development

Seeing the Signal

...ophthalmic diseases in which neovascularization is an issue, VEGF has become the target of choice. Gene Signal...
...September issue of Ophthalmology showed that 86% of patients undergoing corneal graft who were given Gene Signal's...
...Phase III testing of GS-101 has started and is expected to be completed by 2Q10. Gene Signal...
BioCentury | Sep 17, 2009
Distillery Techniques

Technology: Drug delivery

...mice, a conjugate consisting of a TLR9 agonist and an siRNA targeting the immune suppressor gene signal...
BioCentury | Sep 7, 2009
Clinical News

Antisense oligonucleotide: Interim Phase II data

...events. Patients received the drops in 1 eye twice daily. Data were published in Ophthalmology. Gene Signal...
Items per page:
1 - 10 of 16
BioCentury | Jul 24, 2014
Cover Story

It is an RNA world

...antisense oligonucleotide Phase III Topical eye drops Gene Signal International S.A....
...an antisense oligonucleotide Ophthalmic disease Corneal neovascularization Gene Signal International S.A....
...IRS1) mRNA, in Phase III testing by Gene Signal International S.A....
BioCentury | May 19, 2014
Clinical News

Aganirsen: Phase III data

...risk of graft rejection, QOL and complete ophthalmic evaluation scores at day 90 vs. placebo. Gene Signal...
...standard of care (SOC) including corticoids, antiviral and immunosuppressant therapies. Data were published in Ophthalmology. Gene Signal...
...occlusion (CRVO) and Phase II testing to treat wet age-related macular degeneration (AMD). In 2015, Gene Signal...
BioCentury | May 13, 2014
Clinical News

Gene Signal publishes mixed data for aganirsen

...Data published in Ophthalmology showed that twice-daily aganirsen ( GS-101 ) eye drops from Gene Signal International S.A. (Lausanne...
...bacterial, viral or traumatic origin in the intent-to-treat (ITT) population of the double-blind, European trial. Gene Signal...
BioCentury | Apr 28, 2014
Clinical News

Aganirsen: Phase IIa data

...burning or exudation reported. Data were published in The Journal of Pharmacology and Experimental Therapeutics. Gene Signal...
...Aganirsen has also completed a European Phase III trial to treat neovascular-associated corneal graft rejection. Gene Signal International S.A....
BioCentury | May 16, 2013
Distillery Therapeutics

Indication: Cancer

...developing an assay to screen for small molecules that could disrupt the IRS1-mutant p110a interaction. Gene Signal International S.A.'s...
BioCentury | Apr 1, 2013
Strategy

Shire sees opportunity

...for life-altering diseases," Ornskov said. Premiplex is the most advanced ROP program in the clinic. Gene Signal International S.A....
...NYSE:AGN), Irvine, Calif. Bausch & Lomb Inc. , Rochester, N.Y. Bayer AG (Xetra:BAYN), Leverkusen, Germany Gene Signal...
BioCentury | Jan 28, 2013
Financial News

Gene Signal completes venture financing

Gene Signal International S.A. , Lausanne, Switzerland Business: Ophthalmic Date completed: 1/23/13 Type: Venture financing Raised: Not disclosed Investors: Individual investors WIR Staff Ophthalmic...
BioCentury | Sep 21, 2009
Product Development

Seeing the Signal

...ophthalmic diseases in which neovascularization is an issue, VEGF has become the target of choice. Gene Signal...
...September issue of Ophthalmology showed that 86% of patients undergoing corneal graft who were given Gene Signal's...
...Phase III testing of GS-101 has started and is expected to be completed by 2Q10. Gene Signal...
BioCentury | Sep 17, 2009
Distillery Techniques

Technology: Drug delivery

...mice, a conjugate consisting of a TLR9 agonist and an siRNA targeting the immune suppressor gene signal...
BioCentury | Sep 7, 2009
Clinical News

Antisense oligonucleotide: Interim Phase II data

...events. Patients received the drops in 1 eye twice daily. Data were published in Ophthalmology. Gene Signal...
Items per page:
1 - 10 of 16